{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:13Z","timestamp":1788415933717,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cancer immunotherapy has achieved remarkable clinical success; however, therapeutic resistance remains a major challenge. Increasing evidence suggests that gut microbiota-derived metabolites play a critical role in modulating host immune responses and influencing treatment outcomes. This study aimed to systematically characterize the global research landscape and identify emerging trends in this field using bibliometric approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications were retrieved from the Web of Science Core Collection (WoSCC) and Scopus databases based on predefined search strategies. Only English-language articles and reviews were included. Bibliographic records were integrated and deduplicated using the bibliometrix R package. Descriptive analyses were performed to evaluate publication outputs, countries, institutions, authors, and journals. CiteSpace was used for reference burst detection, and VOSviewer was applied to construct keyword co-occurrence networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,979 publications from 1973 to March 2026 were included, comprising 1,593 reviews and 1,386 original articles. China contributed the largest number of publications (1,121; 37.63%), followed by the United States (499; 16.75%). Notably, the United States exhibited the highest H-index and centrality, indicating its leading role in global research impact and collaboration networks. Sichuan University was the most productive institution (115 publications), with six of the top ten institutions located in China. Laurence Zitvogel (28 publications) and Guido Kroemer (22 publications) were the leading authors in this field. Frontiers in Immunology published the highest number of relevant articles (277). Keyword and temporal analyses indicated a shift from descriptive microbiome profiling toward mechanism-oriented and translational research. Recent hotspots include \u201cimmunomodulation\u201d, \u201cthe gut\u2013liver axis\u201d, \u201cintratumoral microbiota\u201d, and \u201cmicrobial metabolites\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Microbial metabolites have emerged as key functional mediators shaping responses to cancer immunotherapy, reflecting a shift from microbiome composition toward metabolite-centered mechanisms. This field is undergoing a transition from descriptive profiling to mechanism-oriented and translational research. These findings provide important insights for developing microbiota-targeted strategies to enhance the efficacy of cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1876450","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:29Z","timestamp":1788412409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global trends and emerging frontiers in cancer immunotherapy and gut microbiota-derived metabolites: a bibliometric analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingying","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhuai","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, the Second Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/08830185.2021.1954638","article-title":"Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system","volume":"41","author":"Ala","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41422-025-01212-6","article-title":"Gut dysbiosis in oncology: a risk factor for immunoresistance","volume":"36","author":"Almonte","year":"2026","journal-title":"Cell Res."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.625913","article-title":"Role and mechanism of gut microbiota in human disease","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946248","article-title":"Gut microbiota, leaky gut, and autoimmune diseases","volume":"13","author":"Christovich","year":"2022","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.chom.2020.12.001","article-title":"The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants","volume":"29","author":"Dohlman","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1675677","article-title":"Microbial metabolites and their influence on the tumor microenvironment","volume":"16","author":"Duan","year":"2025","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.it.2025.12.008","article-title":"Secondary bile acids as immune and metabolic mediators","volume":"47","author":"Fiorucci","year":"2026","journal-title":"Trends Immunol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14217817","article-title":"Gut-liver axis, microbiota, bile acids, and immune response in pathogenesis of primary sclerosing cholangitis: an overview","volume":"14","author":"Fousekis","year":"2025","journal-title":"J. Clin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","article-title":"Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer","volume":"611","author":"Galeano Ni\u00f1o","year":"2022","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/cm9.0000000000003687","article-title":"Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy","volume":"139","author":"Hu","year":"2025","journal-title":"Chin. Med. J. (Engl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01770","article-title":"The chimeric antigen receptor detection toolkit","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2315655","article-title":"Immunotherapy resistance in solid tumors: mechanisms and potential solutions","volume":"25","author":"Lefler","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24958","article-title":"Green roof development knowledge map: a review of visual analysis using CiteSpace and VOSviewer","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-024-01541-w","article-title":"Critical role of the gut microbiota in immune responses and cancer immunotherapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2026.01.001","article-title":"Microbiome-modulated immunotherapy in oncology: current applications and future prospects","volume":"119","author":"Liu","year":"2026","journal-title":"Semin. Cancer Biol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1710880","article-title":"Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","article-title":"Gut-liver axis: barriers and functional circuits","volume":"20","author":"Pabst","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/nu16142372","article-title":"Role of gut microbial metabolites in the pathogenesis of primary liver cancers","volume":"16","author":"Pallozzi","year":"2024","journal-title":"Nutrients"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.3390\/ijms24065550","article-title":"The Ah receptor from toxicity to therapeutics: Report from the 5th AHR meeting at Penn State University, USA, June 2022","volume":"24","author":"Perdew","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nri.2016.42","article-title":"Gut microbiota, metabolites and host immunity","volume":"16","author":"Rooks","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"10609","DOI":"10.1038\/s41467-024-54565-8","article-title":"Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer","volume":"15","author":"Rosario","year":"2024","journal-title":"Nat. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638352","article-title":"Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies","volume":"16","author":"Tong","year":"2025","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.hoc.2023.05.009","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"37","author":"Wala","year":"2023","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/circresaha.124.325212","article-title":"CAR-macrophage therapy alleviates myocardial ischemia-reperfusion injury","volume":"135","author":"Wang","year":"2024","journal-title":"Circ. Res."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1493250","article-title":"A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7150\/thno.119304","article-title":"Short-chain fatty acids in the tumor microenvironment: from molecular mechanisms to cancer therapy","volume":"16","author":"Xiang","year":"2026","journal-title":"Theranostics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1551515","article-title":"Intratumoral microbiota: implications for cancer progression and treatment","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1687901","article-title":"Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities","volume":"19","author":"Yang","year":"2025","journal-title":"Oncol. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","article-title":"Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy","volume":"8","author":"Yang","year":"2023","journal-title":"Signal. Transduct Target Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41522-025-00785-9","article-title":"Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC","volume":"11","author":"Yang","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12964-025-02623-z","article-title":"Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities","volume":"24","author":"Zhai","year":"2026","journal-title":"Cell. Commun. Signal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut microbiota in cancer immune response and immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1876450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:31Z","timestamp":1788412411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1876450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":52,"alternative-id":["10.3389\/fcimb.2026.1876450"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1876450","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1876450"}}